
Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2022, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 37, 21, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 3 molecules, respectively.
Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2022, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 37, 21, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 3 molecules, respectively.
Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
159 Pages
- Introduction
- Global Markets Direct Report Coverage
- Merkel Cell Carcinoma – Overview
- Merkel Cell Carcinoma – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Merkel Cell Carcinoma – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Merkel Cell Carcinoma – Companies Involved in Therapeutics Development
- Affini-T Therapeutics Inc
- Aileron Therapeutics Inc
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Amgen Inc
- Apcure SAS
- Arcus Biosciences Inc
- Aulos Bioscience Inc
- Bavarian Nordic AS
- BeiGene Ltd
- Beijing Advaccine Biotechnology Company Ltd
- BeyondSpring Inc
- BioInvent International AB
- Biosion Inc
- Boston Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- CanWell Pharma Inc
- Centrymed Pharmaceutical Inc
- Checkpoint Therapeutics Inc
- Codiak BioSciences Inc
- CStone Pharmaceuticals Co Ltd
- CytomX Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Exelixis Inc
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fujifilm Holdings Corp
- Genexine Inc
- GI Innovation Co Ltd
- Guangzhou Yinming Biomedical Technology Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- ImmunityBio Inc
- Immunomic Therapeutics Inc
- Incyte Corp
- JSR Life Sciences LLC
- Kartos Therapeutics Inc
- Medicenna Therapeutics Corp
- Memgen Inc
- Merck & Co Inc
- Merck KGaA
- Morphogenesis Inc
- Novartis AG
- Ocellaris Pharma Inc
- OncoSec Medical Inc
- Oncovir Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Philogen SpA
- PokeAcell
- QBiotics Group Ltd
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Seven and Eight Biopharmaceuticals Corp
- Simcha Therapeutics Inc
- SOTIO Biotech AS
- Tarveda Therapeutics Inc
- Treadwell Therapeutics Inc
- Merkel Cell Carcinoma – Drug Profiles
- ADV-510 – Drug Profile
- APC-001 – Drug Profile
- atezolizumab – Drug Profile
- AU-007 – Drug Profile
- avelumab – Drug Profile
- BDB-001 – Drug Profile
- bevacizumab – Drug Profile
- bifikafusp alfa + onfekafusp alfa – Drug Profile
- BMS-986415 – Drug Profile
- BOS-342 – Drug Profile
- BOXR-1030 – Drug Profile
- BSI-060T – Drug Profile
- BT-001 – Drug Profile
- cabozantinib s-malate – Drug Profile
- CAN-1012 SR – Drug Profile
- CDK-003 – Drug Profile
- Cellular Immunotherapy 2 for Oncology – Drug Profile
- Cellular Immunotherapy for Solid Tumors – Drug Profile
- cemiplimab – Drug Profile
- CFI-402411 – Drug Profile
- cosibelimab – Drug Profile
- davoceticept – Drug Profile
- DNV-3 – Drug Profile
- efineptakin alfa – Drug Profile
- envafolimab – Drug Profile
- etrumadenant – Drug Profile
- FT-538 – Drug Profile
- G-100 – Drug Profile
- GI-101 – Drug Profile
- IFx-Hu20 – Drug Profile
- ipilimumab – Drug Profile
- ipilimumab + nivolumab – Drug Profile
- ITI-3000 – Drug Profile
- lenvatinib mesylate – Drug Profile
- LY-3434172 – Drug Profile
- MCPyV – Drug Profile
- MDNA-11 – Drug Profile
- MEM-288 – Drug Profile
- navtemadlin – Drug Profile
- Neoantigen Peptide Vaccine – Drug Profile
- nivolumab – Drug Profile
- nofazinlimab – Drug Profile
- nogapendekin alfa – Drug Profile
- OC-001 – Drug Profile
- pacmilimab – Drug Profile
- pazopanib hydrochloride – Drug Profile
- pembrolizumab – Drug Profile
- pembrolizumab biosimilar – Drug Profile
- PEN-221 – Drug Profile
- PF-07265807 – Drug Profile
- plinabulin – Drug Profile
- Poke-102 – Drug Profile
- Poly-ICLC – Drug Profile
- PRJ-13024 – Drug Profile
- retifanlimab – Drug Profile
- SB-11285 – Drug Profile
- SOT-101 – Drug Profile
- ST-067 – Drug Profile
- sulanemadlin – Drug Profile
- talimogene laherparepvec – Drug Profile
- tavokinogene telseplasmid – Drug Profile
- tigilanol tiglate – Drug Profile
- tislelizumab – Drug Profile
- topotecan hydrochloride – Drug Profile
- tuparstobart – Drug Profile
- Vaccine to Target Brachyury for Oncology – Drug Profile
- Vaccine to Target WT1 for Oncology – Drug Profile
- vidutolimod – Drug Profile
- vusolimogene oderparepvec – Drug Profile
- zimberelimab – Drug Profile
- Merkel Cell Carcinoma – Dormant Projects
- Merkel Cell Carcinoma – Discontinued Products
- Merkel Cell Carcinoma – Product Development Milestones
- Featured News & Press Releases
- Nov 08, 2022: Immunomic Therapeutics receives FDA fast track designation for ITI-3000, a pDNA vaccine, in development for the treatment of Merkel cell carcinoma
- Jul 21, 2022: Immunomic doses first subject in Phase I Merkel cell carcinoma vaccine trial
- Apr 08, 2022: Immunomic Therapeutics reports preclinical data on its MCPV-LT vaccine at the American Association for Cancer Research (AACR) Annual Meeting 2022
- Mar 31, 2022: Immunomic Therapeutics announces ITI-3000 poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
- Mar 15, 2022: PharmaJet Partner Immunomic Therapeutics initiates clinical trial of DNA vaccine for skin cancer
- Feb 08, 2022: Immunomic to investigate asset in Phase I Merkel cell carcinoma trial
- Nov 01, 2021: Data from Incyte’s Oncology portfolio accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
- Oct 20, 2021: Checkmate Pharmaceuticals announces webcast on innate immune modulators and Vidutolimod (CMP-001)
- May 19, 2021: EMD Serono to present on BAVENCIO at ASCO21
- Apr 10, 2021: Codiak presents data at AACR 2021 demonstrating potential of engineered exosomes to enhance the therapeutic index of well-validated cancer immunotherapy pathways
- Dec 30, 2020: Codiak reports positive initial phase 1 results for exoIL-12 demonstrating tolerability and absence of systemic IL-12 exposure in healthy volunteers
- Dec 21, 2020: New publication in Molecular Cancer Therapeutics highlights data from preclinical development of exoIL-12 for the treatment of cancer
- Nov 09, 2020: Codiak presents preclinical data at SITC 2020 demonstrating potential of engEx engineered exosomes to stimulate targeted, integrated anti-tumor immunity
- Nov 02, 2020: Immunomic Therapeutics to present at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs
- Jun 11, 2020: Immunomic Therapeutics to present at AACR virtual annual meeting II
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Merkel Cell Carcinoma, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Universities/Institutes, 2022
- Table 11: Number of Products by Stage and Target, 2022
- Table 12: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 13: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 16: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 17: Number of Products by Stage and Route of Administration, 2022
- Table 18: Number of Products by Stage and Molecule Type, 2022
- Table 19: Merkel Cell Carcinoma – Pipeline by Affini-T Therapeutics Inc, 2022
- Table 20: Merkel Cell Carcinoma – Pipeline by Aileron Therapeutics Inc, 2022
- Table 21: Merkel Cell Carcinoma – Pipeline by Alphamab Oncology, 2022
- Table 22: Merkel Cell Carcinoma – Pipeline by Alpine Immune Sciences Inc, 2022
- Table 23: Merkel Cell Carcinoma – Pipeline by Amgen Inc, 2022
- Table 24: Merkel Cell Carcinoma – Pipeline by Apcure SAS, 2022
- Table 25: Merkel Cell Carcinoma – Pipeline by Arcus Biosciences Inc, 2022
- Table 26: Merkel Cell Carcinoma – Pipeline by Aulos Bioscience Inc, 2022
- Table 27: Merkel Cell Carcinoma – Pipeline by Bavarian Nordic AS, 2022
- Table 28: Merkel Cell Carcinoma – Pipeline by BeiGene Ltd, 2022
- Table 29: Merkel Cell Carcinoma – Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2022
- Table 30: Merkel Cell Carcinoma – Pipeline by BeyondSpring Inc, 2022
- Table 31: Merkel Cell Carcinoma – Pipeline by BioInvent International AB, 2022
- Table 32: Merkel Cell Carcinoma – Pipeline by Biosion Inc, 2022
- Table 33: Merkel Cell Carcinoma – Pipeline by Boston Pharmaceuticals Inc, 2022
- Table 34: Merkel Cell Carcinoma – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 35: Merkel Cell Carcinoma – Pipeline by CanWell Pharma Inc, 2022
- Table 36: Merkel Cell Carcinoma – Pipeline by Centrymed Pharmaceutical Inc, 2022
- Table 37: Merkel Cell Carcinoma – Pipeline by Checkpoint Therapeutics Inc, 2022
- Table 38: Merkel Cell Carcinoma – Pipeline by Codiak BioSciences Inc, 2022
- Table 39: Merkel Cell Carcinoma – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
- Table 40: Merkel Cell Carcinoma – Pipeline by CytomX Therapeutics Inc, 2022
- Table 41: Merkel Cell Carcinoma – Pipeline by Eisai Co Ltd, 2022
- Table 42: Merkel Cell Carcinoma – Pipeline by Eli Lilly and Co, 2022
- Table 43: Merkel Cell Carcinoma – Pipeline by Exelixis Inc, 2022
- Table 44: Merkel Cell Carcinoma – Pipeline by F-star Therapeutics Inc, 2022
- Table 45: Merkel Cell Carcinoma – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 46: Merkel Cell Carcinoma – Pipeline by Fate Therapeutics Inc, 2022
- Table 47: Merkel Cell Carcinoma – Pipeline by Fujifilm Holdings Corp, 2022
- Table 48: Merkel Cell Carcinoma – Pipeline by Genexine Inc, 2022
- Table 49: Merkel Cell Carcinoma – Pipeline by GI Innovation Co Ltd, 2022
- Table 50: Merkel Cell Carcinoma – Pipeline by Guangzhou Yinming Biomedical Technology Co Ltd, 2022
- Table 51: Merkel Cell Carcinoma – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
- Table 52: Merkel Cell Carcinoma – Pipeline by ImmunityBio Inc, 2022
- Table 53: Merkel Cell Carcinoma – Pipeline by Immunomic Therapeutics Inc, 2022
- Table 54: Merkel Cell Carcinoma – Pipeline by Incyte Corp, 2022
- Table 55: Merkel Cell Carcinoma – Pipeline by JSR Life Sciences LLC, 2022
- Table 56: Merkel Cell Carcinoma – Pipeline by Kartos Therapeutics Inc, 2022
- Table 57: Merkel Cell Carcinoma – Pipeline by Medicenna Therapeutics Corp, 2022
- Table 58: Merkel Cell Carcinoma – Pipeline by Memgen Inc, 2022
- Table 59: Merkel Cell Carcinoma – Pipeline by Merck & Co Inc, 2022
- Table 60: Merkel Cell Carcinoma – Pipeline by Merck KGaA, 2022
- Table 61: Merkel Cell Carcinoma – Pipeline by Morphogenesis Inc, 2022
- Table 62: Merkel Cell Carcinoma – Pipeline by Novartis AG, 2022
- Table 63: Merkel Cell Carcinoma – Pipeline by Ocellaris Pharma Inc, 2022
- Table 64: Merkel Cell Carcinoma – Pipeline by OncoSec Medical Inc, 2022
- Table 65: Merkel Cell Carcinoma – Pipeline by Oncovir Inc, 2022
- Table 66: Merkel Cell Carcinoma – Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Table 67: Merkel Cell Carcinoma – Pipeline by Pfizer Inc, 2022
- Table 68: Merkel Cell Carcinoma – Pipeline by Philogen SpA, 2022
- Table 69: Merkel Cell Carcinoma – Pipeline by PokeAcell, 2022
- Table 70: Merkel Cell Carcinoma – Pipeline by QBiotics Group Ltd, 2022
- Table 71: Merkel Cell Carcinoma – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 72: Merkel Cell Carcinoma – Pipeline by Replimune Ltd, 2022
- Table 73: Merkel Cell Carcinoma – Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022
- Table 74: Merkel Cell Carcinoma – Pipeline by Simcha Therapeutics Inc, 2022
- Table 75: Merkel Cell Carcinoma – Pipeline by SOTIO Biotech AS, 2022
- Table 76: Merkel Cell Carcinoma – Pipeline by Tarveda Therapeutics Inc, 2022
- Table 77: Merkel Cell Carcinoma – Pipeline by Treadwell Therapeutics Inc, 2022
- Table 78: Merkel Cell Carcinoma – Dormant Projects, 2022
- Table 79: Merkel Cell Carcinoma – Dormant Projects, 2022 (Contd..1)
- Table 80: Merkel Cell Carcinoma – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Merkel Cell Carcinoma, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Top 10 Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Top 10 Molecule Types, 2022
- Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.